Condition (MeSH)
T-Lymphocytopenia, Idiopathic CD4-Positive
ClinicalTrials.gov lists 10 trials for T-Lymphocytopenia, Idiopathic CD4-Positive or a narrower condition beneath it. National Institute of Allergy and Infectious Diseases (NIAID) has the most among industry and government lead sponsors, with 5.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
10 of the 10 trials are tagged with T-Lymphocytopenia, Idiopathic CD4-Positive itself; the rest are tagged with a narrower condition beneath it.
When did T-Lymphocytopenia, Idiopathic CD4-Positive trials start? (9)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Not applicable
- Observational
Top of scale: 2
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2025 | 1 |
| 2024 | 1 |
| 2023 | 1 |
| 2020 | 1 |
| 2019 | 1 |
| 2017 | 1 |
| 2013 | 1 |
| 2009 | 2 |
| 1992 | 1 |
No forecast is made for this condition: it averages 0.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are T-Lymphocytopenia, Idiopathic CD4-Positive trials in? (5)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 1/2 | 2 |
| Phase 2 | 1 |
| Not applicable | 1 |
| Observational | 5 |
How many T-Lymphocytopenia, Idiopathic CD4-Positive trials are recruiting? (4)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 4 |
| Completed | 4 |
| Suspended | 1 |
| Terminated | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most T-Lymphocytopenia, Idiopathic CD4-Positive trials? (1)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | 5 |
Which drugs are being tested for T-Lymphocytopenia, Idiopathic CD4-Positive? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Pyridostigmine | 1 |
| CYT107 | 1 |
| Belimumab | 1 |
Interventions as named in the registry (2)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Recombinant human interleukin (IL) 7-hyFc | 1 |
| Constitution of a biobank of frozen cells, plasma and serum samples | 1 |
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do T-Lymphocytopenia, Idiopathic CD4-Positive trials report? (4)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Acute hypersensitivity reaction | 1 | 1 |
| Gastroenteritis | 1 | 1 |
| Herpes Zoster | 1 | 1 |
| Systemic Lupus Erythematosis | 1 | 1 |
Which publications cover T-Lymphocytopenia, Idiopathic CD4-Positive? (8)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Prevalence and pathogenicity of autoantibodies in patients with idiopathic CD4 lymphopenia. | The Journal of clinical investigation | 2020 | Yes |
| Administration of interleukin-7 increases CD4 T cells in idiopathic CD4 lymphocytopenia. | Blood | 2016 | Yes |
| Second messenger role for Mg2+ revealed by human T-cell immunodeficiency. | Nature | 2011 | Yes |
| Idiopathic CD4+ lymphocytopenia may be due to decreased bone marrow clonogenic capability. | International archives of allergy and immunology | 2005 | Yes |
| Lymphocyte diversity in a 9-year-old boy with idiopathic CD4+ T cell lymphocytopenia. | International archives of allergy and immunology | 2001 | Yes |
Showing 5 of 8 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.